Literature DB >> 8187353

Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted?

E Honkanen1, T Törnroth, C Grönhagen-Riska, R Sankila.   

Abstract

72 adult patients with idiopathic membranous glomerulonephritis (iMGN), 92% having proteinuria 3 g/24 h or more, were studied for the clinical evolution of the disease and factors which might be involved in the development of chronic renal insufficiency (CRI). At 10 years, 46% were in complete or partial remission, 4% had the nephrotic syndrome (NS), 26% had some degree of CRI, and 24% were dead or started on dialysis. The actuarial patient and kidney survival rates were 80% and 64%, respectively at 10 years. Patient survival rate was not affected by gender, age (after adjustment for age- and sex-matched population) or the severity of NS at diagnosis. 20 patients showed CRI and apart from the more frequent (p < 0.05) presence of CRI at diagnosis, no clinical features discriminated them from those having intact renal function. Furthermore, no clinical factors at diagnosis predicted the final renal function among the 72 patients. However, it appeared that the evolution of clinical status of iMGN was rapid CRI appearing 1.4 (median, range from 0 to 15.1) years after the diagnosis. At one and two years, renal function correlated significantly (r = 0.54, p < 0.0001 at two years) with the final renal function. What is more, the type of the evolution of proteinuria over the first two years gave valuable information on the eventual deterioration of renal function. Patients having stable non-nephrotic grade proteinuria and those in whom NS disappeared, had excellent renal outcome while those in particular showing an increased severity of NS had poor prognosis in terms of renal survival.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8187353

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

1.  The natural history of the non-nephrotic membranous nephropathy patient.

Authors:  Michelle A Hladunewich; Stephan Troyanov; Jennifer Calafati; Daniel C Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-06       Impact factor: 8.237

Review 2.  Treatment of severe lupus nephritis: the new horizon.

Authors:  Tak Mao Chan
Journal:  Nat Rev Nephrol       Date:  2014-11-25       Impact factor: 28.314

3.  Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy.

Authors:  Shin'ichi Akiyama; Mari Akiyama; Enyu Imai; Takenori Ozaki; Seiichi Matsuo; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2014-11-21       Impact factor: 2.801

4.  Analysis of the prognostic risk factors of idiopathic membranous nephropathy using a new surrogate end-point.

Authors:  B O Zhang; Ming Cheng; Ming Yang; Shuai Han; Ying-Hui Zhang; Hong-Guang Shi; Liang Zhu; Xue-Zhi Zhao
Journal:  Biomed Rep       Date:  2015-12-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.